At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NDRA ENDRA Life Sciences Inc
Post-Mkt 12-11 18:52:23 EST
5.92
+0.06
+1.02%
盘后5.81
-0.11-1.86%
16:59 EST
High5.94Low5.52Vol57.68K
Open5.64D1 Closing5.86Amplitude7.17%
Mkt Cap6.91MTradable Cap6.91MTotal Shares1.17M
T/O334.27KT/O Rate4.95%Tradable Shares1.17M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ENDRA Life Sciences Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  12-08
ENDRA Life Sciences Is Maintained at Buy by Ascendiant Capital
ENDRA Life Sciences Reports TAEUS Device Matches MRI Accuracy in Liver Disease Study
Reuters  ·  12-04
ENDRA Life Sciences Reports TAEUS Device Matches MRI Accuracy in Liver Disease Study
ENDRA Life Sciences Inc - Second Feasibility Study for Taeus Liver Device Begun in London, Ontario
THOMSON REUTERS  ·  12-04
ENDRA Life Sciences Inc - Second Feasibility Study for Taeus Liver Device Begun in London, Ontario
ENDRA’s Taeus® Liver Matches Mri-Pdff Performance at Key Clinical Thresholds, Positioning Device for Masld/Mash Trial Use
THOMSON REUTERS  ·  12-04
ENDRA’s Taeus® Liver Matches Mri-Pdff Performance at Key Clinical Thresholds, Positioning Device for Masld/Mash Trial Use
ENDRA Life Sciences CTO Resigns as CFO Compensation Terms Change
Reuters  ·  11-29
ENDRA Life Sciences CTO Resigns as CFO Compensation Terms Change
ENDRA Life Sciences Reports Positive Feasibility Study Results for TAEUS Liver Fat Quantification Device
Reuters  ·  11-20
ENDRA Life Sciences Reports Positive Feasibility Study Results for TAEUS Liver Fat Quantification Device
ENDRA Life Sciences Q3 EPS $(2.10) Misses $(1.95) Estimate
Benzinga  ·  11-17
ENDRA Life Sciences Q3 EPS $(2.10) Misses $(1.95) Estimate
ENDRA Life Sciences reports third quarter cash burn down 30% to $1.2 million
Reuters  ·  11-17
ENDRA Life Sciences reports third quarter cash burn down 30% to $1.2 million
Press Release: ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
Dow Jones  ·  11-17
Press Release: ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
ENDRA Life Sciences Raises $4.9 Million in Private Placement
Reuters  ·  11-15
ENDRA Life Sciences Raises $4.9 Million in Private Placement
ENDRA Life Sciences Commences Staking of its HYPE Digital Assets
MT Newswires Live  ·  11-14
ENDRA Life Sciences Commences Staking of its HYPE Digital Assets
ENDRA Life Sciences Outlines Ongoing Digital Asset Strategy with Plans to Stake HYPE Tokens, Enhance Balance Sheet Diversification, and Explore Further DeFi Opportunities
Reuters  ·  11-13
ENDRA Life Sciences Outlines Ongoing Digital Asset Strategy with Plans to Stake HYPE Tokens, Enhance Balance Sheet Diversification, and Explore Further DeFi Opportunities
BRIEF-ENDRA Life Sciences Inc Enters ATM Agreement With Lucid For Up To $1.75 Million - SEC Filing
Reuters  ·  10-30
BRIEF-ENDRA Life Sciences Inc Enters ATM Agreement With Lucid For Up To $1.75 Million - SEC Filing
ENDRA Life Sciences Inc -on Oct 29, Enters Atm Agreement With Lucid for up to $1.75 Mln - SEC Filing
THOMSON REUTERS  ·  10-30
ENDRA Life Sciences Inc -on Oct 29, Enters Atm Agreement With Lucid for up to $1.75 Mln - SEC Filing
ENDRA Life Sciences Raises $4.9 Million in Private Placement and Launches Crypto Treasury Strategy
Reuters  ·  10-23
ENDRA Life Sciences Raises $4.9 Million in Private Placement and Launches Crypto Treasury Strategy
ENDRA Life Sciences Closes up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy With $3 Million in Initial Hype Token Holdings
THOMSON REUTERS  ·  10-23
ENDRA Life Sciences Closes up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy With $3 Million in Initial Hype Token Holdings
ENDRA Life Sciences Inc. Announces Date for Upcoming Annual Stockholder Meeting
Reuters  ·  10-18
ENDRA Life Sciences Inc. Announces Date for Upcoming Annual Stockholder Meeting
ENDRA Life Sciences Issues Correction to October 15, 2025, SEC Filing to Address Technical Submission Error
Reuters  ·  10-16
ENDRA Life Sciences Issues Correction to October 15, 2025, SEC Filing to Address Technical Submission Error
ENDRA Life Sciences Announces $14.4 Million Private Placement to Launch Digital Asset Treasury Strategy Managed by Arca
Reuters  ·  10-15
ENDRA Life Sciences Announces $14.4 Million Private Placement to Launch Digital Asset Treasury Strategy Managed by Arca
Top Premarket Decliners
MT Newswires Live  ·  10-14
Top Premarket Decliners

Introduction

Company Name.
ENDRA Life Sciences Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Issue price:
--